What You Should Know:
– mPATH® Health, a digital health company dedicated to improving cancer screening, is thrilled to announce the successful closure of $3 million in funding, which will accelerate the company’s mission to enhance cancer prevention and improve health equity.
– This funding includes a $2 million Small Business Technology Grant from the National Cancer Institute (NCI) and a $1 million equity investment led by Oncology Ventures, an oncology-focused venture capital firm.
mPATH Health Secures Funding to Enhance Cancer Screening and Prevention Programs
mPATH Health, a digital health company dedicated to revolutionizing preventive cancer screening through automation and behavioral science, has received a significant boost in its mission to improve early cancer detection. By utilizing advanced technology and personalized outreach, mPATH empowers individuals to prioritize their health and undergo routine cancer screenings. The platform’s unique approach has proven effective in doubling screening rates across diverse populations, including those of different races, ethnicities, income levels, and literacy backgrounds.
In July 2024, mPATH Health was awarded a National Cancer Institute (NCI) grant to support the commercialization of its innovative cancer screening program. This funding will enable continued development and rigorous clinical testing of the platform, further validating its ability to increase cancer screening rates in underserved communities.
– The NCI grant, a pivotal endorsement of mPATH’s technology, will be instrumental in advancing the platform’s effectiveness across various demographic groups.
Additionally, mPATH Health secured $1 million in funding from Oncology Ventures, an investment firm dedicated to improving cancer care access, outcomes, and cost-efficiency. This investment will accelerate mPATH’s growth and facilitate the development of new screening and preventive health modules.
– With this financial support, mPATH Health is well-positioned to expand its reach and impact, promoting health equity by delivering improved outcomes for patients from all backgrounds.
These milestones mark a pivotal moment in mPATH Health’s journey to transform cancer prevention, ensuring broader access to life-saving screenings and empowering individuals to take charge of their health.
“We are incredibly proud of the recognition from the NCI and the investment from Oncology Ventures,” said Dr. David Miller, co-founder of mPATH. “This $3 million funding will allow us to rapidly expand our reach, increase cancer screenings, and ultimately save lives. It will also enhance our program and ensure that we can document its return on investment for health systems and insurers.”
